Key Developments: Affymetrix Inc (AFFX.O)

AFFX.O on Nasdaq

8.83USD
11 Jul 2014
Price Change (% chg)

$-0.06 (-0.67%)
Prev Close
$8.89
Open
$8.86
Day's High
$8.92
Day's Low
$8.75
Volume
269,346
Avg. Vol
970,594
52-wk High
$9.80
52-wk Low
$3.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Affymetrix, Inc and Leica Biosystems Announce the Launch of Fully Automated RNA
Thursday, 8 May 2014 05:30am EDT 

Affymetrix, Inc:Affymetrix, Inc and Leica Biosystems launches Affymetrix' fully automated RNA in situ hybridization assays ViewRNA eZ Assays on Leica BOND RX staining platform.These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues.Dedicated for research use only, assays provide researchers with powerful automated solution for drug discovery, translational research, and development of new diagnostic tests for personalized medicine.Automation significantly reduces hands-on time and assay run time for profiling single-cell gene expression.  Full Article

Affymetrix, Inc reaffirms FY 2014 guidance - Conference Call
Thursday, 1 May 2014 05:00pm EDT 

Affymetrix, Inc:Says it remain committed to achieving revenue and EBITDA targets for FY 2014.FY 2014 revenue of $336 million and EBITDA of $46 million - Thomson Reuters I/B/E/S.  Full Article

Enzo Biochem announces settlement agreement with Affymetrix
Thursday, 24 Apr 2014 09:45am EDT 

Enzo Biochem Inc:Enters into settlement with Affymetrix, Inc. with respect to actions between the company and Affymetrix before the U.S. District Court.In settlement of the aforementioned cases, Affymetrix will pay $5,100,000.  Full Article

CollabRx and Affymetrix partner to develop analytical tools
Wednesday, 16 Apr 2014 09:05am EDT 

CollabRx Inc:Partners with Affymetrix to optimize the use of CollabRx's Genetic Variant Annotation (GVA) Service(tm) in connection with Affymetrix' OncoScan(tm) FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation (CNV) in cancer research.Overall objective of the partnership is to enable the GVA Service to accept and process gene CNV data directly from OncoScan assays and CytoScan assays to provide scientific knowledge for biomarker CNV profiles in cancer.  Full Article

Affymetrix Inc gives FY 2014 guidance; EBITDA guidance above analysts' estimates - Conference Call
Wednesday, 5 Feb 2014 05:00pm EST 

Affymetrix Inc:Expects FY 2014 top-line revenue to be about $335 million.Expects FY 2014 EBITDA in the range of 12pct to 13pct.The company reported EBITDA of $52.64 million.FY 2014 revenue of $334 million and EBITDA of $49.9 million - Thomson Reuters I/B/E/S.  Full Article

Affymetrix Inc receives FDA Clearance of First-of-its-kind postnatal test for developmental delays and intellectual disabilities in children
Tuesday, 21 Jan 2014 06:00am EST 

Affymetrix Inc:Says it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan Dx Assay.Says this assay is intended for the postnatal detection of DNA copy number variants (CNV) in patients referred for chromosomal testing.Says CytoScan Dx Assay is designed to help physicians diagnose children`s developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations.Says high resolution analysis can reveal small aberrations not readily seen using traditional techniques.  Full Article

University of Bristol Collaborates with Affymetrix on Genotyping Arrays for Guaranteed Sustainability of Wheat Production
Monday, 13 Jan 2014 05:00am EST 

Affymetrix Inc:Says that they have collaboratively designed a wheat genotyping array and analyzed data from experiments as part of an effort to understand wheat genetics and breeding with a goal of ensuring guaranteed sustainable production.  Full Article

Affymetrix Inc issues Q4, FY 2013 revenue guidance above analysts' estimates
Tuesday, 7 Jan 2014 06:00am EST 

Affymetrix Inc:Sees Q4 2013 revenue to be approximately $91 million, including a one-time licensing payment of $5.3 million from a diagnostic partner.Sees FY 2013, revenue of approximately $329 million.Revenues of $82.60 million for Q4 2013 and revenues of $320 million for FY 2013 - Thomson Reuters I/B/E/S Estimates.  Full Article

StoneCalibre Acquires Anatrace From Affymetrix Inc
Monday, 14 Oct 2013 09:15am EDT 

StoneCalibre announced that the completion of the acquisition of Anatrace, a part of Affymetrix, Inc. Headquartered in Maumee, Ohio, Anatrace is a developer, manufacturer and global distributor of purity detergents and synthetic lipids for use in membrane protein studies. The terms of the transaction were not disclosed.  Full Article

Affymetrix Inc Appoints Gavin Wood As Executive Vice President And CFO
Monday, 20 May 2013 06:00am EDT 

Affymetrix Inc announced that it has appointed Mr. Gavin Wood to the position of Executive Vice President and Chief Financial Officer (CFO). Tim Barabe, the current CFO, is expected to retire from Affymetrix effective June 28, 2013.  Full Article

Search Stocks